Modine Manufacturing Company vs GeneDx Holdings Corp — how do they compare? Modine Manufacturing Company trades at $184.56 (market cap $10.06B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: Modine Manufacturing Company is far larger — about 4.9× GeneDx Holdings Corp's market cap, and Modine Manufacturing Company is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Modine Manufacturing Company for 33 Days and GeneDx Holdings Corp for 19 Days on average.
| MOD | WGS | |
|---|---|---|
Market Cap | $10.06B | $2.04B |
Volume | 1,340,605 | 659,215 |
Sector | Industrials | Health |
52-Week High | $283.95 | $167.51 |
52-Week Low | $110.73 | $34.51 |
Typical Hold Time | 33 Days | 19 Days |
Enterprise Value | $10.49B | $2.08B |
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing (MOD) trades at $189.44, down 0.25% on the day, with a neutral technical signal. The stock shows strong fundamental performance, beating earnings estimates for three consecutive quarters, and benefits from a bullish analyst consensus with a $331.25 price target. Recent corporate actions include the completion of a $946 million spin-off of its Performance Technologies unit, potentially streamlining operations for future growth.
The outlook remains positive given earnings momentum and strategic focus on thermal management solutions, but risks include a high P/E ratio of 70.69 and potential integration challenges post-spin-off. Revenue growth to $3.4B in 2026, though with a declining net margin, suggests scaling operations may pressure profitability near-term.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →